Literature DB >> 32393495

Early Oral Antibiotic Switch for Staphylococcus aureus Bacteremia: Many Are Called, but Few Are Chosen.

Thomas L Holland1,2.   

Abstract

Staphylococcus aureus bacteremia (SAB) is a complicated, high-risk disease. For selected low-risk SAB, the role of oral antibiotic stepdown therapy is unknown. Bupha-Intr et al. report a retrospective cohort of low-risk SAB patients who did well with a short duration of intravenous antibiotics, followed by an additional ∼10 days of oral antibiotics, primarily using beta-lactams. Prospective trials will help further define the efficacy of this approach.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Staphylococcus aureus; bloodstream infections

Mesh：

Substances：

Year:  2020        PMID： 32393495      PMCID： PMC7317999          DOI： 10.1128/AAC.00317-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Epidemiology of central line-associated bloodstream infections in Quebec intensive care units: a 6-year review.

Authors:  Patricia S Fontela; Robert W Platt; Isabelle Rocher; Charles Frenette; Dorothy Moore; Elise Fortin; David Buckeridge; Madukhar Pai; Caroline Quach
Journal:  Am J Infect Control       Date:  2011-08-06       Impact factor: 2.918

2.  Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.

Authors:  Thomas L Holland; Issam Raad; Helen W Boucher; Deverick J Anderson; Sara E Cosgrove; P Suzanne Aycock; John W Baddley; Anne-Marie Chaftari; Shein-Chung Chow; Vivian H Chu; Manuela Carugati; Paul Cook; G Ralph Corey; Anna Lisa Crowley; Jennifer Daly; Jiezhun Gu; Ray Hachem; James Horton; Timothy C Jenkins; Donald Levine; Jose M Miro; Juan M Pericas; Paul Riska; Zachary Rubin; Mark E Rupp; John Schrank; Matthew Sims; Dannah Wray; Marcus Zervos; Vance G Fowler
Journal:  JAMA       Date:  2018-09-25       Impact factor: 56.272

3.  Efficacy of Early Oral Switch with β-Lactams for Low-Risk Staphylococcus aureus Bacteremia.

Authors:  Olivia Bupha-Intr; Tim Blackmore; Max Bloomfield
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

4.  Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.

Authors:  Kasper Iversen; Nikolaj Ihlemann; Sabine U Gill; Trine Madsen; Hanne Elming; Kaare T Jensen; Niels E Bruun; Dan E Høfsten; Kurt Fursted; Jens J Christensen; Martin Schultz; Christine F Klein; Emil L Fosbøll; Flemming Rosenvinge; Henrik C Schønheyder; Lars Køber; Christian Torp-Pedersen; Jannik Helweg-Larsen; Niels Tønder; Claus Moser; Henning Bundgaard
Journal:  N Engl J Med       Date:  2018-08-28       Impact factor: 91.245

5.  Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.

Authors:  Andrew F Shorr; Mark J Kunkel; Marin Kollef
Journal:  J Antimicrob Chemother       Date:  2005-09-29       Impact factor: 5.790

6.  Changing Characteristics of Staphylococcus aureus Bacteremia: Results From a 21-Year, Prospective, Longitudinal Study.

Authors:  Maria Souli; Felicia Ruffin; Seong-Ho Choi; Lawrence P Park; Shengli Gao; Nicholas Christopoulos Lent; Batu K Sharma-Kuinkel; Joshua T Thaden; Stacey A Maskarinec; Lisa Wanda; Jonathan Hill-Rorie; Bobby Warren; Brenda Hansen; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

7.  Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.

Authors:  Steven Y C Tong; David C Lye; Dafna Yahav; Archana Sud; J Owen Robinson; Jane Nelson; Sophia Archuleta; Matthew A Roberts; Alan Cass; David L Paterson; Hong Foo; Mical Paul; Stephen D Guy; Adrian R Tramontana; Genevieve B Walls; Stephen McBride; Narin Bak; Niladri Ghosh; Benjamin A Rogers; Anna P Ralph; Jane Davies; Patricia E Ferguson; Ravindra Dotel; Genevieve L McKew; Timothy J Gray; Natasha E Holmes; Simon Smith; Morgyn S Warner; Shirin Kalimuddin; Barnaby E Young; Naomi Runnegar; David N Andresen; Nicholas A Anagnostou; Sandra A Johnson; Mark D Chatfield; Allen C Cheng; Vance G Fowler; Benjamin P Howden; Niamh Meagher; David J Price; Sebastiaan J van Hal; Matthew V N O'Sullivan; Joshua S Davis
Journal:  JAMA       Date:  2020-02-11       Impact factor: 56.272

8.  Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial.

Authors:  Louise Thorlacius-Ussing; Christian Østergaard Andersen; Niels Frimodt-Møller; Inge Jenny Dahl Knudsen; Jens Lundgren; Thomas Lars Benfield
Journal:  Trials       Date:  2019-05-02       Impact factor: 2.279

9.  Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections - United States.

Authors:  Athena P Kourtis; Kelly Hatfield; James Baggs; Yi Mu; Isaac See; Erin Epson; Joelle Nadle; Marion A Kainer; Ghinwa Dumyati; Susan Petit; Susan M Ray; David Ham; Catherine Capers; Heather Ewing; Nicole Coffin; L Clifford McDonald; John Jernigan; Denise Cardo
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-03-08       Impact factor: 17.586

10.  Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Guy E Thwaites; Matthew Scarborough; Alexander Szubert; Emmanuel Nsutebu; Robert Tilley; Julia Greig; Sarah A Wyllie; Peter Wilson; Cressida Auckland; Janet Cairns; Denise Ward; Pankaj Lal; Achyut Guleri; Neil Jenkins; Julian Sutton; Martin Wiselka; Gonzalez-Ruiz Armando; Clive Graham; Paul R Chadwick; Gavin Barlow; N Claire Gordon; Bernadette Young; Sarah Meisner; Paul McWhinney; David A Price; David Harvey; Deepa Nayar; Dakshika Jeyaratnam; Tim Planche; Jane Minton; Fleur Hudson; Susan Hopkins; John Williams; M Estee Török; Martin J Llewelyn; Jonathan D Edgeworth; A Sarah Walker
Journal:  Lancet       Date:  2017-12-14       Impact factor: 79.321
View more
  1 in total

1.  Efficacy and Safety of Intravenous Lincosamide Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  Isabel Guthridge; Simon Smith; Matthew Law; Enzo Binotto; Josh Hanson
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.